These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 26477312)

  • 1. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
    Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms.
    Tripathi P; Wang Y; Coussens M; Manda KR; Casey AM; Lin C; Poyo E; Pfeifer JD; Basappa N; Bates CM; Ma L; Zhang H; Pan M; Ding L; Chen F
    Oncogene; 2014 Apr; 33(14):1840-9. PubMed ID: 23624921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-Regulation of Nfatc1 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Prostate Cancer Cells.
    Liu Y; Liang T; Qiu X; Ye X; Li Z; Tian B; Yan D
    Med Sci Monit; 2019 Feb; 25():1572-1581. PubMed ID: 30817743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
    Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
    PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A basal-enriched microRNA is required for prostate tumorigenesis in a Pten knockout mouse model.
    Fan X; Bjerke GA; Riemondy K; Wang L; Yi R
    Mol Carcinog; 2019 Dec; 58(12):2241-2253. PubMed ID: 31512783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
    Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
    Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.
    Kawahara T; Kashiwagi E; Ide H; Li Y; Zheng Y; Ishiguro H; Miyamoto H
    Prostate; 2015 May; 75(6):573-84. PubMed ID: 25631176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
    Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
    Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
    Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
    Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
    [No Abstract]   [Full Text] [Related]  

  • 13. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
    Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
    Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.
    Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E
    Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by
    Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate tumorigenesis induced by PTEN deletion involves estrogen receptor β repression.
    Mak P; Li J; Samanta S; Chang C; Jerry DJ; Davis RJ; Leav I; Mercurio AM
    Cell Rep; 2015 Mar; 10(12):1982-91. PubMed ID: 25818291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
    Alimonti A; Nardella C; Chen Z; Clohessy JG; Carracedo A; Trotman LC; Cheng K; Varmeh S; Kozma SC; Thomas G; Rosivatz E; Woscholski R; Cognetti F; Scher HI; Pandolfi PP
    J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
    Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
    Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
    Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
    Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
    Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
    Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.